Xianju Pharmaceutical: Three products are expected to be selected for the twelfth batch of national centralized drug procurement, with the procurement period until the end of 2029.

Xianju Pharmaceutical announced that the company will participate in the 12th batch of national centralized drug procurement bidding on July 31, 2026. The products lamotrigine combined with ethinylestradiol tablets, dydrogesterone tablets, and mesylate betamethasone tablets are expected to be selected. The procurement period for the selected products will be from the enforcement date of the selection results until December 31, 2029. In 2025, the domestic sales amount for lamotrigine combined with ethinylestradiol tablets was approximately 48.58 million yuan, and for dydrogesterone tablets, it was about 3.4122 million yuan; mesylate betamethasone tablets do not have sales yet as they were approved in May 2026. The final results will be subject to the announcement by the centralized procurement office.